TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04050787

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D2 Lymphadenectomy including No. 10
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: D2 lymphadenectomy excluding No. 10
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
Study: NCT03883347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intravenous administration of dexmedetomidine 0.6 mcg / kg within 10 minutes prior to regional anesthesia and 0.6 mcg / kg / h after performing regional anaesthesia until the end of the surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Intravenous administration of remifentanil 1 mcg / kg within 10 minutes prior to regional anesthesia and 0.025 mcg / kg / h after performing regional anaesthesia until the end of the surgery
Study: NCT03245242

Intervention type: OTHER
Intervention: Enhanced Recovery after Surgery
Description: Enhanced Recovery After Surgery (ERAS) protocol is a multi-disciplinary program that aims to standardize care processes around the pre-, intra-, and post-operative care setting. This group will prospectively receive care under a pre-defined protocol.

Intervention type: OTHER
Intervention: Historical usual surgical care
Description: Recent historical controls will have received care under usual care that existed prior to implementation of an enhanced recovery protocol.
Study: NCT02943928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: traditional method by experience
Description: Operator inserted the double lumen tube by experience
Study: NCT02695810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg per day as monotherapy for 13 weeks
Study: NCT01375647

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV
Description: Administered per protocol

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: Administered per protocol

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: Administered per protocol
Study: NCT03555591

Intervention type: DRUG
Intervention: Trelagliptin
Description: Trelagliptin tablets
Study: NCT02695810

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 2 x 850 mg per day as monotherapy for 13 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Interval training, 5 times per week, 30 min per session
Study: NCT03902886

Intervention type: DIAGNOSTIC_TEST
Intervention: gait analysis
Description: gait analysis using an optoelectronic system and a surface EMG

Intervention type: DIAGNOSTIC_TEST
Intervention: gait analysis
Description: gait analysis using an optoelectronic system and a surface EMG
Study: NCT03844386

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.tHIVconsv3
Description: viral-vector, MVA, expressing immunogens derived from conserved yet immunogenic regions of HIV-1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.tHIVconsv3
Description: viral-vector, MVA, expressing immunogens derived from conserved yet immunogenic regions of HIV-1
Study: NCT03980743

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iOTA text messaging intervention
Description: Over 6 months, participants in the iOTA arm will have monthly in-person visits with a health coach who will work with the participant to set goals for the upcoming month related to healthy eating and activity. The participant will receive daily text message health tips related to their goals, and will be prompted once a week to respond with a text indicating their weight and how they are doing with their goals. Following the 6-month active treatment phase, participants will receive text messages only for another 3 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education text messaging intervention
Description: Over 6 months, participants in the Health Ed arm will also have monthly in-person visits with a health coach who will provide education on energy balance and problem-solving. Specific goals will not be set, but the health coach will assist participants in problem-solving any challenges. Participants will receive a weekly automated motivational text message health tip from the study related to what they learned in their health coaching sessions. Following the 6-month active treatment phase, participants will receive text messages only for another 3 months.
Study: NCT02417662

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radical Radiotherapy (Conventional RT and SABR)
Description: Radical radiotherapy (conventional or SABR) to primary and SABR to the metastases

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-investigational SACT
Description: There is no intervention in the control group, patients will receive SACT. The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.
Study: NCT04216563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: Given PO
Study: NCT03987139

Intervention type: OTHER
Group type: OTHER
Intervention: Hypertension
Description: Hypertension is induced by an infusion of noradrenaline within acceptable limits Baseline recording (10 minutes) is performed. MAP gradually increases in steps of 5-10 mmHg during ongoing TCD. When the desired maximum MAP is reached, measurement is made at steady state (10 minutes).~Noradrenaline infusion is stopped. When MAP is stabilized, new baseline is measured for 10 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Hyper- and hypoxia
Description: The mechanical ventilator is adjusted to mild hypoxia, normoxia and mild hyperoxia. Measurements are made for 10 minutes at normoxia and after steady state is reached, respectively. hyperoxia and hypoxia. Oxygenation is controlled by arterial blood gas before and during steady state.

Intervention type: OTHER
Group type: OTHER
Intervention: Hyper- and hypocapnia
Description: The mechanical ventilator is adjusted to a delta PaCO2 on the ventilator for both hypocapnia and hypercapnia. Measurements are made for 10 minutes at normocapnia and after steady state is reached, respectively. hyper- and hypocapnia.
Study: NCT01140594

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photorefractive keratectomy
Description: One eye undergoes wavefront-guided PRK with the Visx S4 CustomVue excimer laser.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photorefractive keratectomy
Description: One eye undergoes wavefront-guided PRK with the Visx S4 CustomVue excimer laser.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser in-situ keratomileusis
Description: One eye undergoes wavefront-guided LASIK using the Visx S4 excimer laser.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser in-situ keratomileusis
Description: One eye undergoes wavefront-guided LASIK using the Visx S4 excimer laser.
Study: NCT03940846

Intervention type: DIAGNOSTIC_TEST
Intervention: Virtual biopsy
Description: Radiomics -the high throughput extraction of quantitative features from medical imaging- extract features that might potentially decode biologic tumor information, which might ultimately reduce the need to use invasive procedure, such as tissue biopsy.

Intervention type: DIAGNOSTIC_TEST
Intervention: Virtual biopsy
Description: Radiomics -the high throughput extraction of quantitative features from medical imaging- extract features that might potentially decode biologic tumor information, which might ultimately reduce the need to use invasive procedure, such as tissue biopsy.

Intervention type: DIAGNOSTIC_TEST
Intervention: Virtual biopsy
Description: Radiomics -the high throughput extraction of quantitative features from medical imaging- extract features that might potentially decode biologic tumor information, which might ultimately reduce the need to use invasive procedure, such as tissue biopsy.

Intervention type: DIAGNOSTIC_TEST
Intervention: Virtual biopsy
Description: Radiomics -the high throughput extraction of quantitative features from medical imaging- extract features that might potentially decode biologic tumor information, which might ultimately reduce the need to use invasive procedure, such as tissue biopsy.
Study: NCT04015817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: paramedical and non-pharmacological services
Description: Paramedical and non-pharmacological services (work on positions, ventilatory education, use of a fan, pulmonary rehabilitation, stress management, mindfulness meditation, psychosocial services, possible support from the mobile palliative care team)
Study: NCT02492191

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone app Recovery Assessment by Phone Points (RAPP)
Description: An e-assessed follow-up of day surgery patients postoperative recovery measured via smartphone app
Study: NCT04193111

Intervention type: DIAGNOSTIC_TEST
Intervention: TMD pain screener
Description: The danish TMD pain screener is given to all participants

Intervention type: DIAGNOSTIC_TEST
Intervention: TMD pain screener
Description: The danish TMD pain screener is given to all participants
Study: NCT01391689

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: diindolylmethane
Description: Given PO

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study: NCT04324541

Intervention type: DIAGNOSTIC_TEST
Intervention: PET scan of the brain with Flortaucipir
Description: PET scan of the brain with non FDA approved Radio tracer.
Study: NCT03574376

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Liposome Injection
Description: Under ultrasound guidance, corresponding ribs will be identified. 3-5 ml of a 1.3% (13.3 mg/mL) of liposomal bupivacaine will be drawn into a syringe with a 1.5-in, 22-gauge needle. The needle will then be advanced 20° cephalad to the skin 3-4 cm lateral to midline at the level of each fractured rib, and 1-2 ribs levels above and below injury. The needle will be advanced 3 mm below the inferior margin of the rib, placing the tip in the space containing the neurovascular bundle. Following negative aspiration for blood or air, 3-5 mL of local anesthetic will be infused and the needle withdrawn. No more than 266 mg, or 20 ml, of the 1.3% (13.3 mg/mL) liposomal bupivacaine solution will be injected

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: The anesthesia department will manage CEA. If possible, the patient will be in the sitting position. The skin will be prepped with chlorhexidine and sterilely draped. 3 mL of lidocaine 1% will be infiltrated the closest interspace to the rib fractures between T4 -T12. A Touhy needle will be inserted, the epidural space identified by loss of resistance technique. An epidural catheter will then be inserted to a depth of 12cm. 3 mL of test solution with lidocaine 1.5% with epinephrine, 1:200,000 will be injected with continuous EKG and SpO2 monitoring. Delivery of a 0.125% bupivacaine solution be continuously infused and titrated based on the patient's clinical status
Study: NCT04257968

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: carotid ultrasonography (IMT and elastography)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI of carotid artery and brain

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neuro Psychological Assessment Battery
Description: Hopkins Verbal Learning Test Digit Span WAIS-IV Stroop Color Word test Trail Making Test Brixton Spatial Anticipation Test Fluency letter (B-D-H) Fluency animal naming Symbol Digit Substitution WAIS-IV

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Questionaires
Description: Cognitive Failures, Depression, Anxiety, Fatigue, Speech handicap, fear for recurrence, Quality of Life.
Study: NCT05420181

Intervention type: OTHER
Group type: OTHER
Intervention: Short 10hr fast
Description: Participants will fast from 11pm the night before the study day

Intervention type: OTHER
Group type: OTHER
Intervention: Long 16h fast
Description: Participants will fast from 5pm the night before the study day
Study: NCT04479059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: follicular fluid flushing
Description: Follicular fluid obtained during OPU will be used for endometrial cavity flushing.
Study: NCT03397524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: optima4BP
Description: optima4BP will provide the treating physician with a treatment action recommendation for consideration.
Study: NCT00232284

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sertraline
Description: RCT of sertraline/placebo for those young people who fail to respond within first 4 weeks of study entry

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Description: RCT of sertraline/placebo for those young people who fail to respond within first 4 weeks of study entry

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioural Therapy
Description: An integrated 10-week CBT program for depression/anxiety and comorbid substance use

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy
Description: An integrated 10-week CBT program for depression/anxiety and comorbid substance use
Study: NCT03844386

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.tHIVconsv4
Description: viral-vector, MVA, expressing immunogens derived from conserved yet immunogenic regions of HIV-1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.tHIVconsv4
Description: viral-vector, MVA, expressing immunogens derived from conserved yet immunogenic regions of HIV-1

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The appropriate amount of Sodium Chloride for Injection USP, 0.9% will be drawn into a syringe.
Study: NCT02430831

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nidina

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04132700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q-NRG Metobolic Cart Device
Description: ICU pateints will be measured using the Q-NRG device for up to 30 mins. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
Study: NCT01194817

Intervention type: DEVICE
Group type: OTHER
Intervention: High-Flexion Knee Replacement System using Cemented Fixation

Intervention type: DEVICE
Group type: OTHER
Intervention: High-Flexion Knee Replacement System using Cementless Fixation
Study: NCT02454127

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Atkins Diet
Description: Dietary counseling for 1 year

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Zone Diet
Description: Dietary counseling for 1 year

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Watchers Diet
Description: Dietary counseling for 1 year

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ornish Diet
Description: Dietary counseling for 1 year
Study: NCT01977274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gynecological cancer
Description: blood and tumor samples
Study: NCT03358186

Intervention type: PROCEDURE
Intervention: surgically treated periprosthetic femur fracture
Description: patients with surgically treated periprosthetic femur fracture
Study: NCT03903705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib in Combination with Sintilimab
Description: Fruquintinib plus Sintilimab:~Cohort A: Fruquintinib 3 mg QD, oral dosing, 3 weeks on/1 weeks off +Sintilimab 200mg Q4W, intravenous dosing.~Cohort B: Fruquintinib 4 mg QD, oral dosing, 3 weeks on/1 weeks off +Sintilimab 200mg Q4W, intravenous dosing~Cohort C: Fruquintinib 5 mg QD, oral dosing, 2weeks on/1 weeks off + Sintilimab 200mg Q3W, intravenous dosing~Cohort E: Fruquintinib 3 mg QD, continuous, oral dosing, + Sintilimab 200mg Q3W, intravenous dosing~Fruquintinib monotherapy arm:~Fruquintinib 5 mg QD, oral dosing, 3 weeks on/1 weeks off~Patients will be treated until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria.
Study: NCT04572906

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NTX-001
Description: One time use surgical product, 3 solutions applied topically, in sequence, to the peripheral nerve repair site, in conjunction with standard suture neurorrhaphy. An isolation chamber medical device (device) is utilized to focus the application of PEG (Solution #2) on the coapted nerve for the required amount of exposure time.
Study: NCT04699240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clotrimazole vaginal tablets
Description: Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotrimazole vaginal tablets+ Lactobacillus
Description: Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months Human Reproductive Tract Active Lactobacillus,4g,qd ,3months
Study: NCT03890289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib Plus Obinutuzumab In Patients With Relapsed/Refractory Follicular Lymphoma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Idelalisib Plus Obinutuzumab In Patients With Relapsed/Refractory Follicular Lymphoma
Study: NCT01576029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CABAZITAXEL (XRP6258)
Description: Pharmaceutical form: solution Route of administration: intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DOCETAXEL (XRP6976)
Description: Pharmaceutical form: solution Route of administration: intravenous
Study: NCT02426138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medically Tailored Meal Delivery (MTM)
Description: Patients will receive delivery of medically tailored meals for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care + Choose MyPlate
Description: Patients will receive usual diabetes care + a Choose MyPlate healthy eating brochure for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care + Choose MyPlate
Description: Patients will receive usual diabetes care + a Choose MyPlate healthy eating brochure for 12 weeks
Study: NCT06290791

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: two level lumbar decompression with BESS procedure received one drain.
Description: patients who underwent two level lumbar decompression with BESS procedure received one drain.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: two level lumbar decompression with BESS procedure received two drain.
Description: patients who underwent two level lumbar decompression with BESS procedure received two drains
Study: NCT04199338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Effect of Web Based Education Based on Self-Care Deficiency Theory on Self-Care Power and Self-Efficacy and Perceived Social Support in Patients Receiving Peritoneal Dialysis
Description: In the study, which will last for 3 months, the patients in the intervention group will receive pre-test Web-based training based on the Self-Care Deficiency Theory. And an intervention group will be expected to use the website weekly. Also weekly reminder messages will be sent regularly.~Following the final test, individuals in the enterprise group will be asked to evaluate their views on the website in writing with the WAMMI test.
Study: NCT03450486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: one 30 minute bout of mild exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: one 30 minute bout of mild exercise
Study: NCT02583113

Intervention type: DEVICE
Intervention: Total and Unicompartment Knee Replacement
Description: Patients who have undergone a primary TKA on one side and primary UKA on the opposite side and are at a minimum of two years post-surgery.
Study: NCT01181154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab (Mabthera®)
Description: 1000 mg at day 1 and day 15

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: equivalent volume total
Study: NCT03275961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management and Resiliency Training
Description: Subjects will undergo an 8 week behavioral program. Treatment will consist of weekly group therapy sessions in small groups with core practices to apply the principles of SMART.
Study: NCT03658109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Bolus Infusion
Description: Patients will undergo Lidocaine Bolus infusion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QL block
Description: Patients will undergo a posterior QL block pre-operatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Bolus Infusion
Description: Patients will undergo Saline Bolus infusion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simulated QL block
Description: Patients will undergo a simulated posterior QL block pre-operatively.
Study: NCT04110743

Intervention type: DEVICE
Group type: OTHER
Intervention: EXPLORER PET/CT
Description: Intervention: PET/CT using different protocols

Intervention type: DEVICE
Group type: OTHER
Intervention: EXPLORER PET/CT
Description: Intervention: PET/CT using different protocols

Intervention type: DEVICE
Group type: OTHER
Intervention: EXPLORER PET/CT
Description: Intervention: PET/CT using different protocols